Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 15, 2026 09:00 ET | Source: ProSomnus Sleep Technologies, Inc.; MonitAir® LLC

ProSomnus® Sleep Technologies and MonitAir® Announce Collaboration to Enhance Connected Care for Obstructive Sleep Apnea

ProSomnus and MonitAir Announce Collaboration to Enhance Connected Care for OSA. Integration supports remote patient monitoring and value-based care.
June 10, 2026 09:30 ET | Source: Beacon Biosignals

Beacon Biosignals Unifies Brands, Bringing CleveMed and SleepView® Under the Beacon Name

CleveMed has joined Beacon Biosignals to advance what is possible in at-home sleep diagnostics.
April 13, 2026 06:00 ET | Source: ProSomnus Sleep Technologies, Inc.

ProSomnus® Receives FDA Class II Clearance for RPMO2 OSA Device

ProSomnus® Receives FDA Class II Clearance for RPMO2 OSA Device
February 24, 2026 09:00 ET | Source: Airway Management, Inc.

TAP Sleep Care Groundbreaking Dual Therapy: Mouth Shield + TAP Improves Oral, Cardiac, and Cognitive Health in OSA

TAP Sleep Care - Groundbreaking Dual Therapy Benefits: Mouth Shield Combined with TAP Devices Improves Oral, Cardiac, and Cognitive Health in OSA patients.
June 03, 2025 07:30 ET | Source: Incannex Healthcare

Incannex Healthcare Inc. Expands IHL-42X Clinical Advisory Board with Appointments of Four Industry and Academic Leaders to Advance Obstructive Sleep Apnea (OSA) Program

NEW YORK and MELBOURNE, Australia, June 03, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company leading the way...
May 29, 2025 07:30 ET | Source: Incannex Healthcare

Incannex Healthcare Inc. Advances IHL-42X RePOSA Trial to Phase 3 Following FDA Protocol Clearance

NEW YORK and MELBOURNE, Australia, May 29, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage pharmaceutical company developing novel combination therapies, today...
May 28, 2025 07:00 ET | Source: Incannex Healthcare

Incannex Healthcare Inc. Enters Agreement to Cancel Remaining Series A Warrants, Eliminating Up to 347.2 Million Shares from Potential Dilution Ahead of IHL-42X Phase 2 Topline Results

MELBOURNE, Australia and NEW YORK, May 28, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company advancing combination drug therapies for...
May 20, 2025 07:30 ET | Source: Incannex Healthcare

Incannex Healthcare Inc. Executes Strategic Cancellation of 50.4% of Series A Warrants, Significantly Reducing Potential Dilution

NEW YORK and MELBOURNE, Australia, May 20, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company pioneering the...
May 15, 2025 08:00 ET | Source: Incannex Healthcare

Incannex Healthcare Inc. Reports Fiscal Third Quarter 2025 Financial Results and Business Updates

NEW YORK and MELBOURNE, Australia, May 15, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing oral...
May 14, 2025 08:00 ET | Source: Incannex Healthcare

Incannex Healthcare Inc. Provides Clinical Program Update on IHL-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (OSA)

Patient dosing completed in Phase 2 portion of Phase 2/3 RePOSA study evaluating IHL-42X oral treatment for OSA.End-of-study follow-up assessments on track for completion by May 17, 2025.Topline...